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Background: HIV infection persists despite antiretroviral treatment (ART) and is reignited as soon as therapies are
suspended. This vicious cycle is fueled by the persistence of viral reservoirs that are invulnerable to standard ART
protocols, and thus therapeutic agents able to target these reservoirs are needed. One such agent, auranofin, has
recently been shown to decrease the memory T-cell reservoir in chronically SIVmac251-infected macaques.
Moreover, auranofin could synergize with a fully suppressive ART protocol and induce a drug-free post-therapy
containment of viremia.
Results: We administered buthionine sulfoximine (BSO), an inhibitor of glutathione synthesis currently in clinical
trials for cancer, in combination with auranofin to chronically SIVmac251-infected macaques under highly-
intensified ART (H-iART). The ART/auranofin/BSO therapeutic protocol was followed, after therapy suspension, by a
significant decrease of viral RNA and DNA in peripheral blood as compared to pre-therapy levels. Drug-free post-
therapy control of the infection was achieved in animals with pre-therapy viral loads ranging from values
comparable to average human set points to levels largely higher. This control was dependent on the presence
CD8+ cells and associated with enhanced levels of cell-mediated immune responses.
Conclusions: The level of post-therapy viral set point reduction achieved in this study is the largest reported so far
in chronically SIVmac251-infected macaques and may represent a promising strategy to improve over the current
“ART for life” plight.
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Antiretroviral therapy (ART) has dramatically improved
the clinical conditions of people living with HIV/AIDS,
but, unfortunately, its effects are not sufficient to elimin-
ate the virus from an infected host. Following therapy
suspension, the virus promptly rebounds to its original
pre-therapy viral set point, thus rendering ART a lifelong
necessity [1]. Since complete elimination of the virus
from the body is still a distant goal, a credible alternative
to current ART regimens could be the induction of a* Correspondence: andrea.savarino@iss.it
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reproduction in any medium, provided the orfunctional cure, i.e. a condition “in which the virus is
not eliminated but is controlled effectively by antiviral
immune responses so that drug treatment can be with-
drawn for prolonged periods of time [2,3]”. Thus, in the
best-case scenario, “functionally cured” individuals should
mirror the ability of a small subset of HIV-infected sub-
jects (i.e. élite controllers) to arrest disease progression
after acute infection in the absence of therapeutic inter-
ventions [4]. It follows that viro-immunological parame-
ters associated with élite control may serve as a useful
term of comparison for the evaluation of intermediate
therapeutic results aiming at a “functional cure”. In this
regard, an animal model recently developed by Pandreatd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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associated with élite control [5].
Apart from peculiar genetic and immunological back-
grounds, it has been apparent since the early Nineteen-
nineties that an obvious correlate of disease progression
is the organism’s total viral burden [6]. Moreover, early
mathematical modelling showed, from the beginning, a
correlation between the extent of the viral burden and
the progression of HIV infection either to an “AIDS re-
gime”, i.e., the loss of immune control of the disease [7], or
to a stalemate between the virus and the immune system,
i.e. an “immune state” reminiscent of a functional cure [7].
However, following the discovery of HIV latency [8], it
became evident that cellular factors should also be
targeted in order to decrease the total virus burden. The
sites for the persistence of latent HIV-1 during ART
lie in the presence of long-lived viral reservoirs (mainly
the memory CD4+ T-cell subpopulations), which harbor
silent copies of proviral DNA that cannot be targeted by
drugs or the immune system. A significant portion of the
proviral DNA burden can be found in two subsets, i.e. the
central and transitional memory T-cells (TCM and TTM,
respectively) [9]. Other cell types, however, have emerged
as potential reservoirs of latent HIV. Among these, mac-
rophages play an important role in viral propagation as
both tissue reservoirs and “Trojan horses” capable of
spreading the virus to the central nervous system (for a
review, see: Ref. [10]). Candidate anti-reservoir strat-
egies, targeting one or many of these viral reservoirs,
may thus exert a profound impact on the viral set point
once ART is suspended [11].
In this regard, we recently showed the potent effects
in chronically SIVmac251 infected macaques of combined
therapeutic protocols targeting both viral replication and
cellular factors [12,13]. Such drug combinations, employing
antiretroviral drugs and the “anti-memory” compound
auranofin, proved able to induce a reduction of the viral
reservoir [12,13] and a decrease in the post-therapy viral
load set point [12]. These in-vivo findings are grounded on
in-vitro experiments revealing the pro-apoptotic and pro-
differentiating effect exerted by auranofin on TCM cells [13]
through induction of oxidative stress [14]. In the present
study, after further elucidating the viro-immunological
effects of auranofin in combination with a highly intensified
ART regimen (H-iART), we decided to enhance the in-vivo
effects of this therapeutic protocol. To achieve this goal, we
used buthionine sulfoximine (BSO), a drug that inhibits the
synthesis of glutathione, an intracellular antioxidant agent
that was previously shown to induce partially selective
killing of infected cells in vitro [15]. This drug, as well as
auranofin, has the relevant advantage of being easily trans-
latable to clinical trials (BSO has been shown to be well
tolerated in vivo in humans [16], while auranofin has long
been employed for treatment of rheumatoid arthritis [17]).We here show that treatment with auranofin and BSO,
in combination with antiretrovirals, results in long-lasting
drug-free control of viremia following therapy suspension.
This control is dependent on the presence of CD8+ cells
and is accompanied by an increase in specific immune
responses.
Results
Combined auranofin/H-iART treatment induces a
profound rearrangement in the CD4+ T-cell
subpopulations
We first analyzed the combined effects of auranofin and
a five-antiretroviral drug regimen, i.e. H-iART, on the T-
lymphocyte subpopulation dynamics and on the im-
munological post-therapy control of viremia. The initial
short-term post-therapy viral set points of these ma-
caques have already been published in Ref. [12].
CD4+ T-lymphocytes of four macaques under auranofin/
H-iART were analyzed by flow cytometry. The combined
auranofin/H-iART therapy induced a significant reduction
in the percentages of naïve cells (TN; Figure 1A) and a
parallel reduction in the TN absolute numbers, although
the latter did not reach statistical significance (Figure 1B).
One of the drugs in the H-iART combination, i.e.
maraviroc, was previously shown to exert a moderate
anti-reservoir effect [12,18] by decreasing antigen-
driven proliferation of CD4+ TCM lymphocytes [12]. We
thus decided to compare the CD4+ T-cell subset dynam-
ics under H-iART/auranofin to those of six historical
controls [13] treated with auranofin and iART (i.e. H-
iART without maraviroc). When compared to animals
treated with H-iART/auranofin, iART/auranofin-treated
macaques displayed a significant increase in the TN per-
centages (Figure 1C). This increase was paralleled by a
decreasing trend in the TCM proportions and by a sig-
nificant restriction of the TEM percentages (Figure 1C).
Absolute cell counts displayed a significant decrease in
the TCM and TEM cell subsets (Figure 1D), in accordance
with the “anti-memory” effect displayed by auranofin
in vitro [13].
In order to gain further insight into the role of auranofin
in the CD4+ T-cell subset dynamics of H-iART/auranofin-
treated macaques, we employed a group of three historical
controls that had received a cycle of H-iART alone [12].
No definite trend over time was displayed in percentages
of any of the subsets (Figure 1E) although absolute cell
numbers of TCM and, to a lesser extent TEM, displayed a
decreasing trend during treatment with H-iART (see
Figure six in Ref. [12]).
We conclude that, although H-iART and auranofin
may independently decrease the memory T-cell subsets,
the combined administration of the two drugs induces
more profound rearrangements in the immune system,
affecting the TN compartment. This is highlighted by
Figure 1 Combined H-iART/auranofin treatment induces
peculiar CD4+ T-cell subpopulation rearrangements in
SIVmac251-infected macaques. Panels A-E. Dynamics over time of
percentages (mean and SEM) and absolute numbers (means and
SEM) of TN (red), TCM (green) and TEM (black) CD4
+ T-cells in
macaques treated with: auranofin and H-iART (Panels A,B); auranofin
and iART, i.e. H-iART without maraviroc (panels C-D); H-iART only
(panel E). Total cell counts of macaques treated with H-iART only
have been presented in Ref. [12]. Panel F. Dynamics over time of the
difference between the average relative proportions of TN and TCM
cells (Δ TN -TCM). Asterisks mark the significant differences with
baseline (i.e., time 0) values (* P < 0.05; ** P < 0.01; *** P < 0.001),
which were calculated by repeated measures ANOVA followed by
Student-Newman-Keuls post-test (panels A-E). Note that percentage
values (panels A, C and E) and absolute values (panels B and D)
were subjected to LOGIT or Log transformation, respectively, before
being subjected to the statistical test. The P value in panel F refers
to the significant difference between curves (extra sum-of-squares F
test) and was calculated after restoring normality with a LOGIT
transformation of the data.
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eter including TN and TCM cells (i.e. Δ TN-TCM) in H-
iART/auranofin-treated macaques as compared to the
other treatment groups (Figure 1F).
Consistent with the subsequent early control of viral
load shown by H-iART/auranofin-treated macaques after
therapy suspension (see next paragraph), the T-cell subset
rearrangements of these macaques are in line with similar
T-cell subset dynamics shown in human élite controllers
displaying depletion of the TN pools, which continuouslyrenovate the memory subsets subjected to increased
turnover [19].
The combination of auranofin and H-iART changes the
pattern of viral rebound and reduces the viral set point
following therapy suspension
To study the effects of auranofin and H-iART on the
post-therapy viral loads, we analyzed the viral dynamics
following suspension of H-iART or H-iART/auranofin.
Figure 2A-E shows an extended post-therapy time course
of the viral loads of macaques treated with H-iART or H-
iART and auranofin.
The H-iART treatment was able to induce a reduction,
although moderate, in the post-therapy viral set point as
compared to pre-therapy levels (Figure 2A,B). This re-
duction is in line with previous findings suggesting that
maraviroc, one of the drugs composing H-iART, is able
to impact on the viral reservoir [12,18,20]. In the animals
that had received H-iART and auranofin (Figure 2C,D),
the decrease in viral set point was higher (0.8 ± 0.2 Log10
viral RNA copies/mL; mean ± S.D) than that of macaques
that had received H-iART alone (0.4 ± 0.6 Log10 viral RNA
copies/mL). The difference, however, was not statistically
significant. In accordance with our previous in-vivo exper-
iments with auranofin [13], the addition of auranofin to
H-iART changed the pattern of post-therapy viral re-
bound. The combination induced a peak reminiscent of
an acute infection-like condition, followed by a decreased
viral set point. Similar to treatments administered during
acute infection in humans and macaques [3,21], additional
H-iART cycles during the viral load peak at rebound in-
duced a further containment of viremia following therapy
suspension as detailed in our previous study (see Ref. [12]
and Figure 2E,F).
An experiment conducted in macaque P177 confirmed
our previous hypothesis that auranofin treatment followed
by H-iART at rebound tilts the virus/immune system bal-
ance in favor of the latter [12], since a temporary depletion
of CD8+ cells at the end of follow-up induced a peak in
viral load (up to 5.9 Log10 viral RNA copies/mL, Figure 2E).
Measurements of the post-depletion viral loads of ma-
caque P177 showed that, following reconstitution of CD8+
cells, the virus was again controlled, though at a level
lower than that observed before the depletion (Figure 2E).
Whether due to the incomplete CD8+ cell reconstitution
that occurred following CD8+ cell depletion (post-deple-
tion = 445.0 ± 41.8 cells/μL; pre-depletion = 707.6 ± 79.9
cells/μL; P < 0.01; Student’s t-test), or due to loss of thera-
peutically induced antiviral responses in the CD8+ cell
compartment, the poorer post-depletion control of viral
load strengthens our published view [12,13] that auranofin
induces active immunologic control of viremia and that
its effects are not limited to a simple reduction of the
reservoir.
Figure 2 Evolution of our treatments of SIVmac251-infected
macaques: effects on the viral load (VL) set points following
treatment interruption. The figure shows the viral load dynamics
of macaques treated with: H-iART alone (Panels A,B), with either a long
(Panel A) or a short (Panel B) cycle; a combined H-iART/auranofin
protocol (Panels C,D); H-iART/auranofin and a short H-iART cycle at
rebound (Panel E); H-iART/auranofin and short H-iART cycles at
rebound and BSO (Panel F); a single cycle of H-iART/auranofin/BSO
(Panels G,H). See main text for further details about the treatment
evolution rationale. Horizontal quotes (in black) mark the viral load set
points (y axes) and the time frames on which their calculations are
based (100 ± 15 days; x axes). The areas under the viral load curve
employed for calculations of the viral set points (see Methods) are
depicted in light blue. The symbol ‘§’ indicates the macaques
simultaneously treated in the controlled pilot study (see main text for
further details). Note that for macaque 4890 (panel H) viral loads were
measured by NASBA, while real-time PCR was adopted for all the
other measurements.
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free containment of viremia following therapy suspension
As the auranofin/H-iART regimen was mainly aimed at
targeting the memory T-cell compartment, we decided to
potentiate our therapeutic strategy and enhance the pro-
oxidant effects of auranofin by adding the glutathione-
depleting agent buthionine sulfoximine (BSO) [15]. The
rationale for the in-vivo use of this drug is supported by a
previous study showing the ability of BSO to selectivelykill productively infected cells in vitro [15], and by new in-
vitro experiments showing that the combination of BSO
and auranofin can induce a “shock and kill” effect on la-
tently HIV-1-infected macrophages (see Additional file 1)
which play a major role in the persistence of HIV/SIV
in vivo [10,22].
We first administered BSO to macaque P252, which
had started antiretroviral treatment before the other study
macaques. BSO was administered after the auranofin
treatment and during an H-iART cycle in temporal vicin-
ity of one rebound in viral load (Figure 2F). The rationale
behind this experiment was that the viral rebound induces
immune activation which in turn prompts viral escape
from latency and consequently renders the infected cells
vulnerable to BSO (for a detailed description of the effects
of BSO on cells escaping latency see Ref. [15]). Moreover,
this experiment allowed an initial evaluation of the effects
of BSO in temporal distance from the previous auranofin
administration for safety reasons. As a result, we observed
an improvement in the drug-free control of viral load fol-
lowing therapy suspension (Figure 2F).
Since the treatment was well tolerated, we devised a sim-
plified therapeutic protocol in which BSO was simultan-
eously administered to both H-iART and auranofin in
macaque P157. This treatment was performed concomi-
tantly to the aforementioned H-iART-only treatment of
macaque P188 and the aforementioned H-iART/auranofin-
only treatments of macaques P185, 4416 and P177. Follow-
ing suspension of H-iART/auranofin/BSO, we observed
a remarkable 2.7-Log reduction in the viral set point
(Figure 2G), much higher than that observed in the
other study subjects (Figure 2A-F).
We then replicated the combined H-iART/auranofin/
BSO therapeutic intervention in another macaque (4890),
using a different viral RNA detecting technique (i.e.
NASBA, see Ref. [23]) to exclude any biases in viral load
detection. The H-iART/auranofin/BSO therapy induced a
drastic reduction in the post-therapy viral set point (3.1
Log10 viral RNA copies/mL at 100 days post-treatment,
Figure 2H), similar to that observed in macaque P157
(Figure 2G). Moreover, the drug-free control of viral load
remarkably improved over time (Figure 2H). Of note, this
result was obtained in an animal starting from a viral load
of 7.3 Log10 RNA copies/mL (i.e. 10 fold higher than viral
loads typically observed in humans with full-blown AIDS).
This result was subjected to an extensive validation to
ensure that post-treatment viral loads obtained in the
chronic phase of the disease did reflect an actual in vivo
phenomenon and were not due to limitations of the tech-
nique. In order to rule out false negative results in 4890,
we first analyzed the relationship between low (<1000
copies of viral RNA/mL) or undetectable viral loads and
the capacity of the assay to detect a viral RNA input run
in parallel. When plasma samples of 4890 showed an
Figure 3 Comparison of the effects of different therapeutic
regimens on the decrease in post-therapy viral set point. The
figure compares the Δ viral load (VL) set point (i.e. the difference
between the pre-therapy and the post-therapy viral load set points)
of macaques subjected to the different therapeutic interventions
described in the manuscript. Data have been analyzed by One Way
ANOVA followed by Newman-Keuls post-test. Of note, macaque
P252, despite being treated with BSO at a later stage, has been
included in the treatment group H-iART + auranofin followed by a
cycle of H-iART at viral rebound to allow performing the statistical
test. However, for this analysis, only the viral set point before
treatment with BSO has been taken into account. Significant
differences are shown by the horizontal quotes.
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erly detected and the quantification of its RNA levels
yielded results that were comparable to the quantity of
input RNA employed, thus proving that the low or un-
detectable viral loads measured in the samples were not
due to technical errors (Additional file 2). Conversely, all
our negative controls resulted in no amplification when
viral loads peaked, supporting the idea that the viral blips
were due to the periodically rebounding virus and not due
to contamination within the assay. Moreover, the results
of our assay are supported by the viro-immunological
correlates, with the major peaks in viral load being accom-
panied by decreases in CD4 counts, and viral load con-
tainment being paralleled by increases in CD4 counts, as
is shown below.
Finally, that the abatement of the viral set point was
associated with the auranofin/BSO treatment is statisti-
cally supported by ANOVA analysis (Figure 3). The
effect of H-iART/auranofin/BSO is also supported by
other statistical tests such as multivariate analysis and
partial correlation analysis, both showing that the num-
ber of drugs simultaneously administered to the ma-
caques was the only independent predictor of the
lowering of the viral set point out of a group of potential
predictors (multivariate analysis: P = 0.012; partial cor-
relation: P = 0.010). Multivariate analysis also reported a
trend between the difference of pre- and post-therapy
viral set points and the total number of therapeutic cy-
cles, although this trend did not reach statistical signifi-
cance (P = 0.095).
Viral load control following suspension of H-iART/
auranofin/BSO is associated with maintenance of
decreased viral DNA levels in peripheral blood
To broaden our knowledge of viral containment fol-
lowing therapy suspension, we analyzed the levels of
viral DNA in PBMCs of six macaques treated with H-
iART/auranofin, with or without BSO. Given the high
potency of the antiretroviral therapy employed in this
study, it was not possible to directly analyze the contri-
bution of auranofin to the decrease in viral DNA during
therapy, which had been demonstrated in a previous
study [13]. This impossibility was derived from the fact
that H-iART alone, before the addition of auranofin, had
per se been able to decrease viral DNA in PBMC below
the sensitivity threshold of our assay, i.e. two copies per
5*105 PBMCs [12]. It was, however, possible to estimate
the contribution of BSO to the post-therapy viral DNA
levels (Figure 4). All animals (n = 3) that had received H-
iART/auranofin/BSO displayed a reduction in post-therapy
viral DNA levels in PBMCs, as compared to pre-therapy
levels (mean reduction: 1.6 Log10 DNA copies, Figure 4).
Instead, only two out of three animals treated with H-
iART/auranofin displayed a reduction in viral DNA,and the extent of this reduction was significantly lower
than that observed in the BSO-receiving group (i.e. 0.5
Log10 DNA copies, Figure 4). We conclude that the
H-iART/auranofin/BSO drug combination decreases
viral DNA in accordance with the improved control of
viremia following therapy suspension.
Treatment with H-iART/auranofin/BSO results in different
CD4+ post-therapy equilibriums following therapy
suspension
We investigated the viro-immunological correlates of
the three animals that had received H-iART/auranofin
and BSO. To this aim, we measured the total CD4+ cell
numbers, the proportion of CD4+ T-lymphocytes over
Figure 4 Comparison of post-therapy viral DNA reduction in
animals treated with H-iART/auranofin (AU) and H-iART/
auranofin/BSO. Delta (Δ) viral DNA is shown as the Log10 difference
between the medians of pre-therapy and post-therapy viral DNA
levels (limit of detection of the assay: 2 DNA copies/5*105 cells).
Means and SEM are displayed in the figure. Pre-therapy values
represent those at start of the H-iART therapy. To avoid biases
(i.e. false negative values), post-therapy values were calculated from
all available measurements (time window: 189 ± 55 days) following
the novel acute infection phase at viral rebound. Data were
analyzed by two tailed Student t-test. Macaques were matched by
similarity of treatments and pre-therapy viral load set point.
Figure 5 Viro-immunological parameters of macaques treated
with H-iART/auranofin and BSO. Depicted are absolute CD4+ cell
counts (blue), proportion of CD4+ T-cells over total lymphocytes
(green), CD4/CD8 ratio (violet), and viral loads (red). Panels A,C,E:
Temporal relationship between viral load and absolute CD4 counts.
Panels B,D,F: Temporal relationship bewtween viral load, proportion
of CD4+ T-cells and CD4/CD8 ratio. The proportion of CD4+ T-cells is
shown in a scale between 0 (i.e. 0%) and 1 (i.e. 100%).
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ing, and after therapy (Figure 5). In the animal to which
BSO had been administered simultaneously with an H-
iART cycle following viral rebound (macaque P252),
CD4+ T-cell counts gradually returned to a level higher
than those prior to therapy but lower than those during
therapy (Figure 5A). The same trend was evidenced by
analyzing the proportion of CD4+ T-cells over total lym-
phocytes and the CD4/CD8 ratio (Figure 5B). One of the
animals that had received a single H-iART/auranofin/
BSO therapeutic cycle (macaque P157) also displayed
the same trend in CD4+ T-cells over time (Figure 5C-D),
but maintained higher CD4 counts (898 ± 227 cells/μL,
mean ± SD; Figure 5C), which were associated with a
higher proportion of CD4+ T-cells and a normal CD4/
CD8 ratio (Figure 5D). This animal was subjected to an
extended follow-up which proved that, one year after
therapy interruption, along with an undetectable viral
load, total CD4+ T-cell counts were still high (i.e. 1210
cells/μL, Figure 5C). The viro-immunological parameters
of this macaque following therapy suspension met the
definition of “functional cure” previously adopted in this
Journal [3].An animal model for a functional cure of AIDS was
recently obtained by Pandrea et al. [5] by infecting non-
natural hosts (Rhesus macaques) with a primate lenti-
virus derived from African green monkeys (SIVagm). In
this model, following an initial viral load peak accompanied
by CD4+ T-cell depletion, viral loads were eventually con-
trolled to undetectable levels for prolonged periods of time,
and CD4 counts gradually increased over time. To investi-
gate whether there might be any similarities between the
model described by Pandrea et al. and the acute infection-
like viral load peak followed by improved containment of
viral load in our macaques, we decided to monitor the
viro-immunological correlates of the early phases of viral
rebound following suspension of H-iART/auranofin/BSO.
Although it was not possible to monitor the early post-
therapy phases of the CD4+ T-cell dynamics in macaque
P157, these phases could be followed-up in the second
animal (macaque 4890) that had received the single H-
iART/auranofin/BSO therapeutic cycle (Figure 5E,F). Al-
though this macaque promptly controlled a major viral
rebound following therapy suspension, it initially displayed
Figure 6 Dynamics over time of CD4+ T-cell subsets in
macaque 4890. Shown are the naïve CD4+ T-cells [naïve-4 (CD28+
CD95-), in yellow], the central memory CD4+ T-cells [cm-4 (CD28
+CD95+), in green] and the effector memory CD4+ T-cells [em-4
(CD28-CD95+), in blue] of macaque 4890, as measured on three
occasions: under therapy (panel A), three months post-therapy
interruption (panel B), eight months post therapy interruption
(panel C).
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tions, and absolute numbers of CD4+ T-cells, as well as the
CD4/CD8 ratio, however, gradually increased over time
(Figure 5F).
As, in the model of Pandrea et al., the CD4+ TEM
subset was the most depleted cell subpopulation during
the acute SIVagm infection, we investigated the dynam-
ics of this T-cell population in macaque 4890. Flow
cytometrical analysis of circulating CD4+T-cells, showed
that the CD4+ TEM cell subset was initially depleted fol-
lowing viral rebound and was reconstituted in parallel to
improvement of viral load control (Figure 6). In conclu-
sion animal 4890 showed an initial acute infection-like
condition after therapy suspension that was followed by
improved control of viral load and an increasing trend
toward normalization of the immunological parameters.
The H-iART/auranofin/BSO-treated macaques P157
and 4890 were still alive at the time when the present
manuscript was written, and had not shown any AIDS-
related events during the follow-up.
Post-therapy control after treatment with H-iART/
auranofin/BSO is likely to be associated with
enhancement of specific immunity
Previous studies have shown the role of specific immun-
ity in viral load containment both during the acute and
chronic phases of the disease [24,25]. We thus analyzed
whether the post-therapy control of viremia following
treatment with H-iART/auranofin/BSO was associated
with changes in specific immune responses. We first
tested the effects of our treatments on the levels of neu-
tralizing antibody titers, assessed in the TZM-bl assay as
described in Ref. [26]. We found that BSO-containing
therapies transiently increased neutralizing antibody ti-
ters in only one of three animals (Additional file 3). No
significant changes (>2.5 fold) were detected in a control
animal treated without BSO (Additional file 3).
We also monitored cellular immune responses to the
Gag protein in animals that had received the combined
H-iART/auranofin/BSO protocol. These animals displayed
a significant increase in SIV Gag-specific ELISpot re-
sponses following treatment interruption, as compared to
animals that had received H-iART/auranofin without BSO
(Figure 7A-C). This increase was sustained for at least
eight months (Figure 7B). Of note, these animals did not
display any of the protective MHC allele combinations
(see Table S1 of Ref. [12]). To further elucidate the contri-
bution of CD8+ cells to the preservation of post-therapy
viral load control, we induced CD8+-cell depletion by
means of a monoclonal α-CD8 antibody [25] in one of the
macaques that had received H-iART/auranofin/BSO
(macaque P157). The depletion of CD8+ cells was accom-
panied by a peak in viral load (up to 4.2 Log10 viral RNA
copies/mL of plasma), while CD8+ T-cell reconstitution
Figure 7 ELISpot detection of gag specific immune responses
of SIVmac251 infected macaques treated with H-iART/auranofin
(AU)/BSO or H-iART/auranofin. PBMCs were stimulated with two
separate SIV Gag peptide pools spanning the entire Gag protein
sequence. Data are presented as the number of spot forming cells
(SFC) per million PBMCs. Panels A,B show the results from macaques
treated with H-iART/auranofin/BSO (Panel A: macaque 4890 and
Panel B: macaque P157). Panel C shows, as a matter of comparison,
the anti-SIV cell-mediated responses of a macaque (P185) that had
been treated with H-iART/auranofin without BSO. Numbers of SFC
per well were normalized per 106 cells after subtracting the average
background (media only) SFC per well. Data were analyzed by
repeated-measures ANOVA, followed by the Student-Newman-Keuls
post-test. Asterisks mark the statistically significant differences
between the baseline levels (during therapy) or those at therapy
interruption) and the post-therapy time points: * P < 0.05; ** P < 0.01;
*** P < 0.001.
Figure 8 Long term post-therapy viral load control following
H-iART/auranofin/BSO treatment is dependent on CD8+ cells.
CD8+-cell depletion was induced in macaque P157 using the anti-
CD8 monoclonal antibody cm-T807. The dotted line parallel to the
x-axis represents the limit of detection for measurement of viral load
(i.e. 40 viral RNA copies/mL of plasma).
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state (Figure 8).
The viral rebound induced by CD8+-cell depletion
was accompanied by a transient CD4+ T-cell depletion
(Figure 8), proving that the virus, although kept at low
or undetectable levels following therapy suspension, was
replication-competent and pathogenic. Moreover, a viral
cultivation experiment using a mixed cell population of
pre-depletion PBMCs and uninfected CEMx174 cells
showed that the virus was both detectable with a p27
ELISA and cytopathogenic (data not shown). We con-
clude that post-therapy control of viremia after suspen-
sion of H-iART/auranofin/BSO was not due to lack of
replicative capacity or infectivity of the virus, and thatCD8+ cell-mediated responses might play a crucial role
to keep the virus in check.
Discussion
Likely advantages of H-iART/auranofin/BSO over previous
regimens
In the present study, we observed a drug-free control of
viremia following suspension of therapies containing anti-
retroviral drugs and agents targeting cellular factors. The
contribution of the glutathione depleting agent BSO to
post-therapy viral load containment was first tested in a
small controlled pilot study in which the animals were sim-
ultaneously treated with therapeutic regimens consisting of
H-iART alone (n = 2) or a combination of H-iART and
auranofin, with (n = 1) or without (n = 3) BSO. The addition
of BSO was associated to an apparent improvement in
post-therapy control of viremia that resulted in a functional
cure-like condition of the treated animal. This observation
is in line with observations deriving from two additional an-
imals that had received BSO and had displayed a reduction
in the post-therapy viral set point of >3 Log10 copies of viral
RNA per mL of plasma. We previously showed that one
similar control can be induced by preventing viral reservoir
re-expansion through a potent antiretroviral (H-iART)
cycle at virus rebound [12]. The current BSO-based ap-
proach, instead, counteracted the rebounding virus likely by
reinforcing the immune responses, as suggested by ELISpot
analyses and shown by the prompt virus rebound that
followed CD8+ cell depletion. However, it should be noted
that the ELISpot assay, despite being a standard tool for
detection of specific immune responses, has the typical lim-
itations common to antigen driven assays, and further ana-
lyses will be necessary for in-depth investigation into the
immune control of the post-therapy viral rebound.
It is as yet unclear whether the boost of the immune
responses is due to auranofin and BSO specifically, or is
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partially immune reconstituted host.
On one hand, immune enhancement by two oxidative
stress-modulators such as auranofin and BSO [27-30] is
not surprising in light of the observation that reactive
oxygen species (ROS; e.g. H2O2 and O
2-) are mitogenic
via changes in protein phosphorylation and/or activa-
tion/inhibition of transcription factors [31]. For example,
the combined use of a pro-oxidant agent (auranofin) and
a GSH depleting one (BSO) may enhance intracellular
H2O2 production, in turn favoring the early events of
lymphocyte activation by inducing NF-κB as well as IL-2
and IL-2 receptor α-chain gene transcription [32]. More-
over, oxidative stress has been previously shown to en-
hance antigen immunogenicity by facilitating antigen
presentation to both MHC I and II [33-36].
On the other hand, the viral rebound following ther-
apy suspension may have acted as an “endogenous”
vaccine able to induce a robust immune response against
the virus. Of note, durable (i.e. >9 months) control of
viral load was observed only in those macaques that had
received both auranofin and BSO.
However, the macaques treated with H-iART/auranofin/
BSO were selected, on purpose, among those starting with
a higher pre-therapy viral load set point in order to high-
light the robustness of the results obtained with this
therapy. This higher pre-therapy viral load set point may
have resulted in an increased antigenic stimulation which,
coupled with the reduction of the viral burden and the
partial immune reconstitution observed during therapy,
may have contributed to the enhanced immune responses
associated with the drug-free control of viremia.
Association between drug-free containment of viremia
and effects on virus-target cells
The enhanced immune response following treatment
with auranofin/BSO is likely to be associated with re-
striction of the circulating pools of viral DNA following
therapy suspension. We previously published results
consistent with a model wherein the elimination of the
memory cell pools (which are a major target for viral
replication, encompass one major viral reservoir and are
exhausted by SIV infection) would have a favorable im-
pact on post-therapy disease progression [13]. Although,
in the present study, the memory T-cell compartment
was targeted by both auranofin and maraviroc, we found
that the H-iART/auranofin regimen mainly affected the
CD4+ TN percentages (Figure 1). This apparent discrep-
ancy may be reconciled by the view that targeting the
memory T-cell compartment by a double mechanism
could spark a compensatory differentiation of TN into
TCM and TEM lymphocytes. That an increased T-cell
turnover results in decreased TN is in line with the re-
stricted TN pools observed in élite controllers, whosememory T-cells are subjected to increased turnover due
to maintenance of viral replication under check [19].
While this increased lymphocyte turnover could con-
tribute to both immune renovation and elimination of
the infected cells, a further rise in this turnover follow-
ing therapy suspension could induce, as a “byproduct”, a
reduction in the T-cell regenerative capacity. These con-
siderations may explain the maintenance of relatively
low T-cell counts in one of the macaques that had re-
ceived H-iART/auranofin/BSO, despite the large de-
crease in the post-therapy viral set point. Our results
are in line with the low CD4+ T-cell counts displayed by
some nonhuman-primate and human élite controllers
[5,19]. Thus, maintenance of CD4 counts to relatively
low levels, but consistent with an unimpaired specific
immunity, may represent a price paid by the host for
keeping viremia under check. Understanding whether
the lowered CD4 counts may provide a target restriction
effect [37] will require further investigation.
Part of the rationale behind our therapeutic strategy is
based on the “shock and kill” effect exerted in vitro by
the combination of auranofin and BSO on infected mac-
rophages (Additional file 1). As these cells are rare, stud-
ies using larger number of macaques will be necessary in
order to allow drawing statistically accurate conclusions
on the effects of our drug combination on this viral
sanctuary in vivo.
Similarities and differences with other conditions of
drug-free remission of AIDS
Elimination/restriction of the virus target cells plus im-
mune restoration represents a promising approach that
has also been followed in order to obtain the first cure
of AIDS in Mr. Timothy Brown, the “Berlin patient” [38].
In that case, CD4+ T-cells were eliminated by total
immune ablation and immune system renovation was
guaranteed by stem cell transplantation. However, the re-
placement of Mr. Brown’s HIV target cells with cells that
the virus cannot infect renders a comparison to our ap-
proach difficult.
Recently, a drug-induced functional cure in the ma-
caque AIDS model has been published by Van Rompay
et al. in this Journal [3]. In the macaques of Van Rompay,
formation of the infected cell pools may have been limited
by the relatively early treatment and decreased virus repli-
cative capacity, and CD8+ cell depletion during therapy
may have induced immune system renovation. A striking
similarity with the results of the present study can be
found in the fact that the macaques of Van Rompay
showed, upon therapy suspension, periodical peaks in viral
load that were followed by containment to very low or
undetectable levels. Similar viral load peaks followed by
containment to undetectable levels were also observed in
other “functional cures” obtained treating early during
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“VISCONTI patients” [39-41]. The amplitude of the peaks
observed is higher in the “functional cures” of macaques
as compared to those described in humans [39,41]. This
discrepancy can be explained by considering the viral
burst size (i.e. the average number of viral particles pro-
duced from a single infected cell), which is one order of
magnitude higher for SIV than for HIV-1 [42]. A visual ex-
ample of these phenomena is shown by the mathematical
simulations in Additional file 4.
Finally, the viro-immunological correlates of one of
our macaques after suspension of treatment with H-
iART/auranofin/BSO were reminiscent of the virus/
CD4+ T-cell dynamics observed in the model of Pandrea
et al. for a functional cure of AIDS in macaques [5],
with CD4+ T-cell depletion associated with higher viral
loads in an initial phase and CD4+ T-cell restoration in
a later phase characterized by improved containment of
viral load.
Conclusions
Our data suggest that a combined H-iART/auranofin/
BSO treatment was followed by a radical change in
disease progression after therapy suspension. This
change was associated with enhanced specific immune
responses following viral rebound after therapy suspen-
sion, thus suggesting the establishment of an “immune
state” [7]. Similar effects had previously been observed
only in the period immediately after acute infection but
not in a pre-AIDS stage [21,39-41]. Although fully con-
trolled studies involving larger numbers of macaques
will be necessary in order to obtain further mechanistic
insight, it is becoming increasingly evident that dra-
matic changes in disease progression cannot be evalu-
ated only in terms of sheer numbers of study subjects
[38,43]. Whether these results may pave the way to a
significant improvement of current “ART-for-life” ther-
apies will need to be assessed in human clinical trials.
Methods
Animal treatment
The Indian rhesus macaques used in this study were
housed at Bioqual, Inc., according to standards and guide-
lines as set forth in the Animal Welfare Act, the Guide for
the Care and Use of Laboratory Animals, and the Associ-
ation for the Assessment and Accreditation of Laboratory
Animal Care (AAALAC), following approval by the Insti-
tutional Animal Care and Use Committee (IACUC). Eight
SIVmac251-infected macaques in the chronic phase of the
infection were enrolled in this study starting from June
2010. The baseline viro-immunological conditions of the
study subjects and their antiretroviral treatments preced-
ing April 2012 have been described in detail in a recent
publication [12]. Macaques in the late chronic phase ofthe infection displaying antiretrovirally suppressed viremia
(i.e. < 50 copies/mL) were kept under highly-intensified
ART (H-iART; consisting of tenofovir, emtricitabine,
raltegravir, ritonavir-boosted darunavir and maraviroc)
and auranofin for three months. Two macaques were
similarly kept under H-iART in the absence of auranofin
to serve as controls. Additional H-iART cycles (mean dur-
ation: 31 days) were administered to animals P177 and
P252 in order to decrease viral reservoir replenishment at
viral rebound. Auranofin (Prometheus Laboratories, San
Diego, CA) was administered by the oral route twice daily
with food (0.4 mg/kg/day). BSO (Sigma-Aldrich, St.Louis,
MO, USA) was administered to three macaques intraperi-
toneally at 450 mg/kg every eight hours for a total of five
administrations (the details of the timing and its ration-
ale are given in the Results section). All animals were
dosed subcutaneously with tenofovir, and emtricitabine,
and orally (with food) with raltegravir, ritonavir-boosted
darunavir, and maraviroc. Drug dosages were: tenofovir,
30 mg/kg/day; emtricitabine, 50 mg/kg/day; raltegravir,
100 mg bid; darunavir, 375 mg bid (for macaques
starting from viral loads lower than 105 viral RNA cop-
ies/mL) or 700 mg bid (for macaques starting from viral
loads higher than 105 viral RNA copies/mL); ritonavir
50 mg bid; maraviroc 100 mg bid. Tenofovir and
emtricitabine were kindly provided by Gilead Sciences
(Foster City, CA). Raltegravir, DRV/r and MRV were
purchased from the manufacturers.
Pilot treatments of macaques P255 and P252 were
conducted in 2010/early 2011. Treatments of macaques
P157, P177, P185, P188, and 4416 were conducted sim-
ultaneously in 2011. An additional SIVmac251-infected
animal (4890) was treated in 2012 in order to ensure re-
producibility of the results.
Macaques P157 and P177 were subjected to CD8+ cell
depletion after therapy suspension in order to study the
contribution of CD8+ cells to post-therapy viral load con-
trol. The depletion was performed with the previously val-
idated antibody cm-T807 ([25,44] kindly provided by the
NIH Nonhuman Primate Reagent Resource center). The
antibody was administered on four different occasions
(days 0, 3, 7 and 10) at 10 mg/kg subcutaneously for the
first administration and at 5 mg/kg intravenously for the
three remaining administrations.
Quantitative assay for SIVmac251 viral RNA levels
For measurement of plasma SIVmac251 RNA levels, a
quantitative TaqMan RNA reverse transcription-PCR (RT-
PCR) assay (Applied Biosystems, Foster City, CA, USA)
was used, which targets a conserved region of the gag
transcripts. The samples were then amplified according to
a method previously described in [12,45]. The sensitivity
of the method is two copies per run, which results in a de-
tection limit as low as 40 RNA copies/mL in our routine
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extensively in Ref. [12]. For the SIV real-time NASBA
assay, macaque plasma was clarified by centrifugation at
2300 × g for 3 mins. The clarified plasma was either lysed
directly (0.1 mL) in lysis buffer (bioMerieux, Durham, NC,
USA) or further centrifuged to pellet virus from a higher
volume (0.5–1 mL) by ultracentrifugation at 49 100 × g for
60 min. The virus pellet was then lysed in 1 mL lysis buf-
fer. A fixed amount of Q calibrator RNA (105 copies or
104 copies) was added to the lysed sample and the nucleic
acid was extracted using acidified silica as described previ-
ously [46]. The quantitative range of the assay was deter-
mined by the concentration of the calibrator added [47].
For samples expected to have a viral load >104 copies/mL,
105 copies of calibrator RNA were used. However, for
lower loads, 104 copies of Q calibrator RNA were used.
The SIV real-time amplification final reaction volume
was 20 μl, containing 5 μl of nucleic acid extract and
40 mM Tris, pH 8.5; 12 mM MgCl2; 90 mM KCl; 5 mM
dithiothriotol; 1 mM each dATP, dCTP, dGTP, dTTP;
2.0 mM each ATP, CTP, UTP; 1.5 mM GTP; 0.5 mM ITP;
0.1 ìg/ìl BSA; 1.5 M sorbitol; 0.08 units RNase H; 32 units
T7 RNA polymerase; 6.4 units avian myeloblastosis virus
reverse transcriptase (AMV-RT); 0.01 μM SIV WT mo-
lecular beacon probe; 0.1 μM SIV Q molecular beacon
probe; 0.2 μM each of the two amplification oligonucleo-
tides, and 15% DMSO. The amplification oligonucleotides
used are as follows—P1: 5′-AATTCTAATACGACTC
ACTATAGGGCACCAGATGACGCAGACAGTATTA-
3′; P2: 5′-CTCCGTCTTGTCAGGGAAGAAAGCA-3′.
The SIV WT molecular beacon has the fluorophore
FAM linked to the 5′ end and a quencher linked to the
3′ end; 5′-FAM-CGATGCATGTAGTATGGGCAGCA
AATGAAGCATCG-DABCYL-3′. The SIV Q molecular
beacon has the fluorophore 6-ROX linked to the 5′ end
and a quencher linked to the 3′ end; 5′-6-ROX-CG
ATGCGTTGAAGTGCAGTAGTGATGGCATCG-DAB
CYL-3′. All reagents, except for enzymes and BSA, were
mixed and preincubated at 65°C for 2 min. The reaction
mixture was then cooled for 2 min at 41°C and the
enzymes and BSA were added. Samples were mixed and
placed in the NucliSENS EasyQ Analyzer (bioMerieux,
Durham, NC, USA) and isothermal amplification took
place at 41°C for 90 min. The NucliSENS EasyQ
Analyzer took measurements throughout the amplifica-
tion reaction, resulting in two fluorescence recovery
curves. An algorithm was then applied that uses the
kinetics of fluorescence recovery from WT and Q RNA
to calculate the SIV RNA copy number in the plasma
samples. The SIV RNA load was expressed as viral RNA
copies per ml plasma. The inter-assay coefficient of
variation of the technique was 19%, well within the
limits of the typical inter-assay variability of SIV RNA
detection techniques [e.g. 12,48].Quantitative assay for SIVmac251 proviral DNA
For proviral DNA detection, DNA was extracted with
the phenol-chloroform method. Quantification was per-
formed by amplifying a region of the gag gene by real
time PCR in a 7700 Sequence Detection System (Ap-
plied Biosystems). Details and validations of the tech-
nique are extensively described in [12,45].
Immunofluorescent staining and flow-cytometric analysis
Hematological analyses were performed by IDEXX (IDEXX
Preclinical Research, North Grafton, MA). For calculation
of absolute CD4+ and CD8+ T-cell numbers, whole
blood was stained with anti-CD3-fluorescein isothio-
cyanate (FITC)/anti-CD4-phycoerythrin (PE)/anti-CD
8-peridinin chlorophyll α protein (PerCP)/anti-CD28-
allophycocyanin (APC), and anti-CD2-FITC/anti-CD20-
PE, and red blood cells were lysed using lysing reagent
(Beckman Coulter, Inc., Fullerton, CA, USA). Samples
were run on a FACSCalibur (BD Biosciences, San Jose,
CA, USA).
Staining for naïve (TN: CD28
+CD95-), central memory
(TCM: CD28
+CD95+), and effector memory (TEM: CD28
-
CD95+) T-cells was performed on PBMCs isolated from
total blood as described in [12]. The mAbs used (BD
Biosciences) were: anti-CD3 (APC-Cy7), anti-CD4 (Per-
CP), anti-CD8 (Pe-Cy7), anti-CD20 (APC), anti-CD28
(FITC) and anti-CD95 (PE). Six-parameter flow-cytometric
analysis was performed on a FACS Canto II instrument
(BD Biosciences). The absolute numbers of TN (CD95
-
CD28+), TCM (CD95
+CD28+) and TEM (CD95
+CD28-)
memory CD4+ T-cells were deduced from percentage
values of parent cells.
Detection of neutralizing antibodies
Sera from different time points during the study were
assayed in the TZM-bl assay system [26] against a
neutralization-sensitive (SIVmac251.6) and a neutralization-
resistant (SIVmac251.30) pseudotyped virus. Virus pseu-
dotyped with Murine Leukemia Virus Env (SVA-MLV) was
included to assess non-SIV-specific neutralizing activity in
the sera. Briefly, serial dilutions of sera from the indicated
time points were pre-incubated with virus (~150,000
relative light unit equivalents) for 1 hr at 37°C. Follow-
ing addition of TZM-bl target cells, the cultures were
incubated for 48 hours, then lysed and assayed for lucif-
erase activity. Neutralization titers are the sample dilu-
tion at which relative luminescence units (RLU) were
reduced by 50% compared to RLU in virus control wells
after subtraction of background RLU in cell control
wells. In several instances, ID50 endpoint titers against
SIVmac251.6 were not achieved in the dilution series
employed in the assays. Thus, an 80% neutralization
titer (ID80) was calculated to expose the relative potency
of the neutralizing antibody response against this virus.
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Specific immune responses were detected by measuring
gamma interferon (IFN-γ) secretion of macaque PBMCs
stimulated with SIVmac239 Gag peptides (125 overlapping
15-mer peptides, obtained through the AIDS Research and
Reference Reagent Program, National Institutes of Health
[NIH]) in an enzyme-linked immunospot (ELISpot) assay.
The peptides were resuspended according to the manufac-
turer’s instructions and divided in two pools (pool 1:
peptides 1–63; pool 2: peptides 64–125). The assay was
performed with the ELISpotPRO for monkey interferon-γ
kit (Mabtech AB, Nacka Strand, Sweden) according to the
manufacturer’s instructions. Briefly, 1.5 × 105 Ficoll isolated
macaque PBMCs were added to 96 well plates pre-coated
with an anti-human/monkey IFN-γ antibody (MAb GZ-4).
Cells were resuspended in RPMI 1640 + 10% FBS with or
without 5 μg/mL of each peptide pool, or concanavalin as
a positive control. Triplicate wells were employed for each
experimental condition. After 48 hours incubation at 37°C
with 5% CO2, the cells were rinsed from the plates, and a
biotinylated anti-human/monkey IFN-γ antibody (MAb 7-
B6-1; Mabtech) was added to the wells. The plates were
then washed with PBS and incubated with the substrate
solution (BCIP/NBT-plus). Spot forming cells (SFC) were
counted by using an automated reader (Immunospot
Reader, CTL analyzers, LLC, Cleveland, OH). Data were
expressed as average numbers of SFC/106 cells after
subtracting the average number of background spots
detected in the negative controls.
Statistical analyses and mathematical simulations
The inter-assay coefficient of variation of the SIV real
time NASBA technique was calculated in accordance
with a standard procedure [e.g. see Ref. [48]. Two differ-
ent control samples (containing ≈ 104.7 and ≈ 102.7 copies
of SIV RNA copies/mL, respectively) were tested in
three different runs per sample. Two coefficients of vari-
ation were calculated from the results of these runs and
the overall coefficient of variation was calculated as the
mean of the two. Differences between variables were cal-
culated using parametric tests (Student’s t-test for com-
parisons between two groups, and ANOVA followed by
the Student-Newman-Keuls post-test for multiple com-
parisons). An appropriate transformation was applied to
restore normality, where necessary. Repeated-measures
tests were used when analyzing matched observations.
Trends were analyzed by regression analysis, followed by
the extra sum-of-squares F post-test. Calculations were
conducted using the software GraphPad Prism 5.00.288
(GraphPad Software, Inc., San Diego, CA, USA).
The viral set point was calculated using the area-under
-curve (AUC) method using the GraphPad (v.5) soft-
ware. To ensure consistency in the results obtained, we
considered the post-therapy viral load values in the sametime interval as that of the available pre-therapy values.
The time frames analyzed in the different macaques
were largely comparable, since the standard deviation of
the periods considered accounted for only 15% of the
mean value. To ensure accuracy in the analyses, the
starting value employed for calculation of the post-therapy
vial load set point was selected according to the following
criteria:
1) For animals that had received auranofin, and had
therefore experienced the previously published acute-
infection-like condition [13], we started the follow-up im-
mediately after the acute-infection-like peak in viremia.
This choice mimics calculations of the viral set point in
the natural course of the infection, discarding the acute in-
fection phase as non-representative of the equilibrium
reached thereafter. The initial value adopted for our viral
load set point calculations was the minimum in the curve
after the initial peak.
2) For animals that had the initial viral load peak
abated artificially by H-iART, the period under drugs
was not taken into account, and the viral set point calcu-
lations were started after therapy withdrawal.
3) For animals that had not received auranofin and for
which there was no clear initial peak, follow-up was
started when viremia plateaued. This allowed discarding
the initial values and providing a sensible comparison with
the data from the auranofin-treated animals. We consid-
ered that the plateau was reached when viral load reached
values above 80% of the asymptote of the one-phase asso-
ciation curve describing the viral rebound and obtained by
non-linear regression analysis option embedded in the
GraphPad software. Additional file 5 provides an illus-
trated example of the method adopted.
For each of the cases presented in 1), 2) and 3), the in-
put values were analyzed using the “area under curve”
option in the GraphPad software. Peaks accounting for
less than 10% of the AUC were automatically discarded
by the default option of the software adopted. To allow
an overall comparison of the results obtained, results
were normalized by dividing by the length of the tem-
poral window.
Multivariate analysis was used to study the contribu-
tion of independent predictors to the post-therapy viral
load set point and the difference between the pre- and
post-therapy viral load set points points (Δ viral set point).
The analysis was conducted with the IBM SPSS software
(v. 21, Armonk, NY, USA), using a type-I regression par-
ameter, and the post-therapy viral set point and the Δ viral
set point as dependent variables. The choice of the poten-
tially predicting parameters was based on literature ana-
lysis. Possibly independent predictors were considered to
be the number of drugs simultaneously employed, the
total duration of therapy (i.e. the number of days during
which macaques were exposed to drugs), the number of
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A “therapy” was considered to be a sequence of thera-
peutic cycles wherein the distance between neighboring
treatments did not exceed 90 days. Partial correlation
analysis was conducted using SPSS, starting from the
same parameters, and controlling by the total duration of
therapy.
For a discussion of mathematical methods and numer-
ical tools employed in the numerical simulations, see the
“Statistical and biomathematical analyses” paragraph in
the “Materials and methods” section and Text S1 in Ref.
[12]. See also Ref. [50]. Briefly, for our simulations we
adjusted for a macaque model the system of ordinary
differential equations (system 4) introduced in [50]. In
this system, a random step function is used to simulate
the periods in which there is activation of resting latently
infected CD4+ T-cells. The activation function used in
the simulations was generated with the RANDLIB pack-
age of the Scilab 5.3.3 software (freely available at www.
scilab.org). This function is shown in the figure of
Additional file 6. Further information on mathematical
modeling is given in the text of Additional file 6 while
the starting data employed for the numerical simula-
tions are shown in Additional file 7.Additional files
Additional file 1: Auranofin and BSO induce a “shock and kill”
effect on monocyte-derived macrophages. This additional file
describes the in-vitro experiments conducted on macrophages.
Additional file 2: Validation of NASBA sensitivity over time.
Comparison between the input number of viral RNA copies employed as
positive controls and the output value (viral RNA copies/mL) yielded by
the NASBA assay for each positive control. All the positive controls
shown were run in parallel with the plasma samples of macaque 4890
that yielded an undetectable viral load (i.e. < 50 viral RNA copies/mL).
Additional file 3: Neutralizing antibody titers in SIVmac251-infected
macaques before and after treatment with H-iART/auranofin (AU)
with or without BSO.
Additional file 4: Numerical simulations of the Rong and Perelson
model with programmed expansion and contraction of the viral
reservoir. All simulations are based on Ref. [50], including the parameters
adopted for the viral burst size in macaques and humans. Panels A,B
show the typical disease progression in a macaque (A) and a human (B)
model. According to our previous study [12], the death rate of
productively infected CD4+ T-cells in the macaque model is assumed to
be 7.20 day-1. In both scenarios there is no control of the infection, and a
clear increase (of about 3 Logs) of the latent reservoir is observed. For
starting data, see Additional file 7, while, for a thorough discussion of the
parameters and for the activation function used, see Additional file 6.
Panels C,D illustrate a theoretical situation in which the death rate of
productively infected CD4+ T-cells (which can be interpreted as a
measure of the immune response to the virus) is increased of about
tenfold. Note that CD4 counts are referred to 1 mL of blood and are
expressed in the Log scale. To allow a visualization in Log scale, all the
graphs have been shifted upwards (+0.1).
Additional file 5: Criteria for the calculation of the post-therapy
viral set points in macaques subjected to different types of
treatment. This additional file illustrates the criteria employed for the
calculation of the viral set points following therapy interruption.Additional file 6: Mathematical modeling. This additional file provides
detailed information on the mathematical modeling procedures and
rationale.
Additional file 7: Starting data for the numerical simulation of the
viral load/T-cell dynamics in SIVmac251-infected macaques.
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